Consort Completes Acquisition of Aesica Holdco Ltd
Consort has completed the acquisition of Aesica Holdco Ltd.
The board considers that the acquisition represents an excellent opportunity for Consort and is directly in line with Consort's articulated strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain.
Aesica is one of Europe's leading pharmaceutical contract development and manufacturing organisations (CDMO), providing contract development and manufacturing services for finished dose and APIs to the global pharmaceutical industry. Since the Aesica business was established in 2004, it has grown both organically and through acquisitions and has established key strategic relationships with major global blue-chip pharmaceutical companies.
Jon Glenn, Consort's CEO, said: "We are excited by the acquisition of Aesica which represents a very strong fit with our existing strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain. As one of Europe's leading pharmaceutical CDMOs, Aesica is highly complementary to Bespak's existing business and provides a number of clear strategic, competitive and value-enhancing benefits for the Enlarged Group."
Dr Robert Hardy, Chief Executive, Aesica said: “We are proud of what we have accomplished over the last decade, developing Aesica through a combination of organic growth, continuous process improvement and investment. We continue to see many exciting opportunities in the pharmaceutical contract manufacturing sector and we look forward to pursuing these under the ownership of Consort Medical. Our position as a pharmaceutical CDMO is now further strengthened in the global market place through the alignment Aesica has with Bespak, as part of the enlarged Consort Medical group. With our collective strengths we will continue to provide high quality pharmaceutical contract development and manufacturing services internationally."
Capitalised terms not defined herein, are defined at Part XVIII of the combined shareholder prospectus and circular published by the Company on 30 September 2014.
Related News
-
News Women in Pharma: Hiring Across the Gender Divide
In our monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
Sponsored Content Ashwagandha and Herbal Medicines: Pharma’s Next Big Opportunity
Herbal medicines and nutraceuticals have seen a surge in interest since the onset of the COVID-19 pandemic. Driven by patient interest in prioritising personalised and integrative medicines, the herbal ingredients industry is now faced with concerns pe... -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News Updated – Changing abortion pill access according to the US FDA and Supreme Court
After the approval of the medical abortion pill, mifepristone, by the US FDA, states across the USA approach the distribution of the pill differently, some ruling against allowing access to the drug. -
News Revolutionising cancer treatment with mRNA-based therapeutics
Global market for mRNA-based oncology therapeutics expected to reach USD $2 billion by 2029, with promising results for the combination of mRNA candidates with immune checkpoint inhibitors to treat solid tumours. -
News Breaking Barriers: Innovations in Oral Solid Dose Form Bioavailability
The effectiveness of a medication often hinges on its bioavailability – the rate and extent at which the active ingredient is absorbed into the bloodstream. When it comes to oral solid dose forms, such as tablets and capsules, the challenge lies ... -
News Choosing the Right CDMO Partner: A Comprehensive Guide
Finding the right partner for the development and manufacturing of your pharmaceutical or biopharmaceutical products is paramount. This is where Contract Development and Manufacturing Organizations (CDMOs) step in, offering their expertise and infrastr...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance